Operating cash flow of $146.7M in Q2 2026 far exceeded the net loss, yielding a negative OCF/NI ratio of -5.58, while FCF improved to $124.5M, reflecting strong cash conversion despite earnings volatility.
Herbalife Nutrition Ltd. (HLF) cash flow statement — 23-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 |
|---|
| Cash from Operations | 497.6M | 333.3M | 285.4M | 357.5M | 352.5M | 460.3M | 628.6M | 457.5M | 648.4M | 590.8M | 367.3M | 628.7M | 511.4M | 772.88M | 567.78M | 509.33M | 380.4M | 285.06M | 272.99M | 270.81M | 184.45M | 143.35M | 80.22M | 94.65M |
| Operating CF Margin % | - | 6.62% | 5.72% | 7.06% | 6.77% | 7.93% | 11.34% | 9.38% | 13.25% | 13.34% | 8.18% | 14.07% | 10.31% | 16.02% | 13.94% | 14.74% | 13.91% | 12.26% | 11.57% | 12.62% | 9.78% | 9.15% | 6.13% | 8.16% |
| Operating CF Growth % | 56933.55% | 16.78% | -20.17% | 1.42% | -23.42% | -26.77% | 37.4% | -29.44% | 9.75% | 60.85% | -41.58% | 22.94% | -33.83% | 36.12% | 11.48% | 33.89% | 33.45% | 4.42% | 0.8% | 46.82% | 28.67% | 78.69% | -15.24% | - |
| Net Income | 164.2M | 227.8M | 254.3M | 142.2M | 321.3M | 447.2M | 372.6M | 311M | 296.6M | 213.9M | 260M | 339.1M | 308.7M | 527.52M | 477.19M | 412.58M | 290.53M | 203.35M | 221.19M | 191.45M | 143.14M | 93.14M | -14.31M | 36.85M |
| Depreciation & Amortization | 150.2M | 121.2M | 121.4M | 113.3M | 115.4M | 107.6M | 100.3M | 97.7M | 100.4M | 99.8M | 98.3M | 98M | 93.2M | 84.74M | 74.38M | 71.85M | 68.62M | 62.44M | 49.21M | 35.45M | 30.34M | 36.83M | 50.75M | 62.64M |
| Stock-Based Compensation | 42.8M | 44.1M | 50M | 48M | 44.4M | 54.1M | 51M | 38.6M | 35.5M | 42.1M | 40.2M | 44.9M | 45.7M | 29.49M | 27.91M | 24.13M | 22.97M | 20.91M | 17.79M | 12.9B | 11.3B | 0 | 32.51T | 0 |
| Deferred Taxes | -55.1M | -64.2M | -229.6M | -41.1M | -29.9M | -33.3M | 2M | 15.4M | -8.1M | 97.8M | -36.4M | -38.2M | -84.8M | -24.91M | -9.05M | -12.98M | -24.63M | -11.23M | -4.1M | 3.34M | -19.54M | -12.46M | 3.62M | -12.16M |
| Other Non-Cash Items | 151.3M | 39.9M | 56.8M | 47.4M | 24.4M | 103M | 62.5M | 57M | 144.8M | 85.2M | 63.1M | 114.8M | 285.3M | 23.3M | -25.23M | -13.92M | -5.39M | 2.37M | 2.6M | -12.92B | -11.3B | 5.34M | -32.51T | 8.51M |
| Working Capital Changes | -16.4M | -35.5M | 32.5M | 47.7M | -123.1M | -218.3M | 40.2M | -62.2M | 79.2M | 52M | -57.9M | 70.1M | -136.7M | 132.73M | 22.59M | 27.67M | 28.3M | 7.22M | -13.7M | 58.52M | 37.05M | 20.49M | 5.08M | -1.19M |
| Change in Receivables | -35.3M | -19.7M | 5.9M | -9.1M | -9.1M | 9.6M | 121.1M | 19.9M | 127.3M | -22.2M | 23.1M | -6.2M | 6M | 9.22B | -28.19B | -9.69B | -7.59B | 2.36B | -18.53B | -2.38B | -12.23B | 0 | 4T | 0 |
| Change in Inventory | -13.6M | -27.9M | -30.4M | 57.5M | -68.4M | -129.1M | -76.6M | -68.6M | -83.3M | 37.9M | -71.6M | -30.5M | -99.4M | -39.88M | -82.18M | -84.88M | -31.52M | -1.74M | -27.57M | 26.77M | -29.94M | -40.25M | -7.57M | 592K |
| Change in Payables | -4M | 24.1M | -14.6M | -7.4M | -1.1M | 6.9M | 5.5M | 100K | 21.7M | -5M | -1.3M | 6M | -5.2M | 10.84M | 17.03M | 15.43M | 6.65M | -9.5M | 8.92M | -7.59B | -1.89B | 0 | 449B | 0 |
| Cash from Investing | -83.3M | -108.7M | -84.6M | -134.8M | -156.2M | -156.4M | -123.2M | -108M | -83.9M | -97.8M | -141.3M | -73.4M | -201.3M | -150.82M | -125M | -92.09M | -69.14M | -71.32M | -84.96M | -43.39M | -66.81M | -32.53M | -9.38M | 2.85M |
| Capital Expenditures | -72.4M | -80.4M | -122M | -135M | -156.4M | -151.4M | -112M | -106.1M | -84M | -95.5M | -143.4M | -79M | -173.7M | -146.96M | -121.52M | -90.41M | -68.13M | -59.77M | -88.6M | -41.94M | -62.46M | -31.54M | -23.08M | -13.6M |
| CapEx % of Revenue | 1.39% | 1.6% | 2.44% | 2.67% | 3.01% | 2.61% | 2.02% | 2.18% | 1.72% | 2.16% | 3.19% | 1.77% | 3.5% | 3.05% | 2.98% | 2.62% | 2.49% | 2.57% | 3.76% | 1.95% | 3.31% | 2.01% | 1.76% | 1.17% |
| Acquisitions | -10M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 400K | 0 | 0 | 0 | 0 | 0 | -10M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -900K | -28.3M | 37.4M | 200K | 200K | -5M | -11.2M | -1.9M | 100K | -2.3M | 2.1M | 5.7M | -15M | 186K | -3.48M | 297K | -1.01M | -1.55M | 3.64M | -1.45M | -4.35M | -990K | 13.7M | 15.19M |
| Cash from Financing | -241.8M | -295.5M | -335.3M | -148.3M | -264.7M | -728.6M | -320.9M | -713M | -593.1M | -85.2M | -252.3M | -250M | -389.5M | 30.74M | -371.24M | -337.8M | -254.48M | -213.33M | -205.07M | -203.51M | -55.04M | -225.89M | -21.98M | -18.83M |
| Debt Issued (Net) | 61.7M | -284.2M | -305.5M | -138.7M | -115M | 286.9M | 607M | -699.5M | 128.2M | 779.5M | -238.8M | -227.6M | 1.07B | 443.7M | 284.1M | 25.34M | -72.45M | -101.11M | -49.56M | 170.61M | -87M | -227.44M | 142.56M | -23.04M |
| Equity Issued (Net) | -3.9M | -8.2M | -8.3M | -11M | -146.7M | -1.01B | -923.5M | -16.7M | -750.3M | -844.2M | -13.2M | -16.6M | -1.29B | -306.5M | -545.35M | -299.38M | -160.01M | -74.64M | -138.92M | -365.78M | 11.77M | 2.13M | 203.11M | 4.21M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -30.4M | -123.06M | -135.09M | -85.49M | -53.74M | -48.72M | -50.7M | -41.53M | 0 | 0 | -184.54M | 0 |
| Share Repurchases | -3.9M | -8.2M | -8.3M | -11M | -146.7M | -1.01B | -923.5M | -16.7M | -750.3M | -844.2M | -13.2M | -16.6M | -1.29B | -306.5M | -556.8M | -321.64M | -160.01M | -74.64M | -138.92M | -365.78M | 0 | 0 | 0 | 0 |
| Other Financing | -299.6M | -3.1M | -21.5M | 1.4M | -3M | -4.2M | -4.4M | 3.2M | 29M | -20.5M | -300K | -5.8M | -135.9M | 16.6M | 25.1M | 21.73M | 31.72M | 11.15M | 34.11M | 33.19M | 20.18M | -586K | -183.12M | 0 |
| Net Change in Cash | 147.4M | -62.8M | -157.4M | 79.2M | -94.1M | -443.6M | 206.5M | -367.5M | -80.5M | 434.8M | -45.8M | 244.4M | -327.6M | 639.44M | 74.76M | 68.22M | 39.75M | -46K | -36.56M | 33.08M | 66.08M | -113.33M | 50.9M | 86.48M |
| Free Cash Flow | 425.2M | 252.9M | 163.4M | 222.5M | 196.1M | 308.9M | 516.6M | 351.4M | 564.4M | 495.3M | 223.9M | 549.7M | 337.7M | 625.92M | 446.26M | 418.92M | 312.28M | 225.29M | 184.39M | 228.87M | 121.99M | 111.82M | 57.14M | 81.05M |
| FCF Margin % | 8.18% | 5.02% | 3.27% | 4.4% | 3.77% | 5.32% | 9.32% | 7.21% | 11.54% | 11.19% | 4.99% | 12.3% | 6.81% | 12.97% | 10.96% | 12.13% | 11.42% | 9.69% | 7.82% | 10.67% | 6.47% | 7.14% | 4.36% | 6.99% |
| FCF Growth % | 148.07% | 54.77% | -26.56% | 13.46% | -36.52% | -40.21% | 47.01% | -37.74% | 13.95% | 121.21% | -59.27% | 62.78% | -46.05% | 40.26% | 6.53% | 34.15% | 38.61% | 22.18% | -19.44% | 87.62% | 9.1% | 95.68% | -29.5% | - |
| FCF per Share | 4.07 | 2.44 | 1.61 | 2.22 | 1.97 | 2.85 | 3.84 | 2.48 | 3.78 | 2.99 | 1.30 | 3.22 | 1.86 | 2.91 | 1.89 | 1.68 | 1.23 | 0.89 | 0.70 | 0.79 | 0.41 | 0.39 | 0.27 | 0.38 |
| FCF Conversion (FCF/Net Income) | 2.59x | 1.46x | 1.12x | 2.51x | 1.10x | 1.03x | 1.69x | 1.47x | 2.19x | 2.76x | 1.41x | 1.85x | 1.66x | 1.47x | 1.19x | 1.23x | 1.31x | 1.40x | 1.23x | 1.41x | 1.29x | 1.54x | -5.61x | 2.57x |
| Interest Paid | 0 | 0 | 194.4M | 159.1M | 133.5M | 143.5M | 78.9M | 114.3M | 106.1M | 100.7M | 45.4M | 50.5M | 39.2M | 23M | 14.3M | 8.8M | 9.29M | 10.01M | 17.73M | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 146.5M | 133.1M | 144.9M | 156.3M | 138.2M | 147.9M | 158.9M | 158.8M | 162.9M | 168.4M | 180.8M | 197.1M | 169.7M | 118.91M | 111.5M | 95.14M | 73.94M | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying HLF stock.
Herbalife Nutrition Ltd. (HLF) generated $333.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Herbalife Nutrition Ltd. (HLF) generated $252.9M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Herbalife Nutrition Ltd. (HLF) spent $80.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Herbalife Nutrition Ltd. (HLF) spent $8.2M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Margin compression and EPS volatility
Metrics are mathematically derived from official filings.
Cash Conversion Diverges Sharply
In Q2 2026, operating cash flow of $146.7M vastly exceeded the net loss of $26.3M, yielding an OCF/NI ratio of -5.58, according to recent financial statements, suggesting non-cash charges and working capital swings are masking underlying cash generation.
The negative net income in Q2 2026 appears to be driven by non-cash items such as depreciation, amortization, and possibly impairments or tax effects, while operating cash flow remained robust. This divergence suggests that the reported loss may not reflect the company's cash-generating ability, but investors should monitor whether this pattern persists or if it indicates one-time charges. The high OCF/NI ratio in Q2 2026 contrasts sharply with the 0.39 ratio in Q4 2024, indicating significant quarterly volatility in earnings quality.
Free Cash Flow Rebounding from Weakness
Free cash flow improved to $124.5M in Q2 2026, a 70% increase from the prior quarter, as reported in the cash flow statement, with FCF margin expanding to 9.4% from 7.8%, suggesting a recovery from the negative FCF in Q1 2025.
The trajectory of free cash flow has been uneven, with negative FCF in Q1 2025 and Q1 2024, but recent quarters show a rebound. The Q2 2026 FCF of $124.5M is the highest in the ten-quarter period, indicating that working capital releases and controlled capex are boosting cash generation. However, the sustainability of this improvement is uncertain given the stagnant revenue growth and the need to service debt.
Capital Expenditures Remain Subdued
Capital expenditures averaged 1.8% of revenue over the last ten quarters, with Q2 2026 at 1.7%, according to the cash flow data, indicating a low capital intensity that supports free cash flow but may limit long-term growth investments.
The low capex-to-revenue ratio suggests that Herbalife is not investing heavily in expansion or modernization, which could be a deliberate strategy to maximize cash flow in a mature business. However, this may also indicate underinvestment in digital capabilities or supply chain resilience, which could become a competitive disadvantage. The decline from 2.8% in Q2 2024 to 1.7% in Q2 2026 suggests a tightening of capital spending, possibly to preserve cash for debt reduction.
Working Capital Swings Drive Cash Flow
Working capital changes swung from a $73.1M use of cash in Q2 2026 to a $4.1M source in Q1 2026, as per the cash flow statement, indicating significant volatility in collections, inventory, and payables that materially impacts quarterly cash flow.
The large negative working capital change in Q2 2026 suggests a build-up in inventory or a slowdown in collections, which consumed cash despite strong operating income. Conversely, Q1 2026 saw a small positive contribution, and Q4 2025 had a $36.7M source, indicating that the company's cash conversion cycle is not stable. This volatility may reflect distributor purchasing patterns or promotional timing, and investors should monitor whether it indicates a structural deterioration in working capital efficiency.
Capital Deployment Focused on Buybacks
Share repurchases totaled $10.0M in Q2 2026, with no dividends paid, according to the cash flow statement, indicating a continued preference for buybacks over dividends, though the pace has slowed from prior years.
The company has consistently used cash for share repurchases, but the amounts are modest relative to free cash flow, suggesting a cautious approach given the leveraged balance sheet. The absence of dividends and the small buyback activity in Q2 2026 may indicate that management is prioritizing debt reduction or preserving liquidity. The $10.0M acquisition in Q2 2026 is notable, but the overall deployment strategy appears to be conservative, which may be prudent given the margin pressures.
Cumulative Cash Generation Exceeds Earnings
Over the last ten quarters, cumulative operating cash flow of $879.0M exceeded cumulative net income of $518.2M, as per the cash flow data, indicating that earnings understate cash generation, likely due to non-cash charges and working capital timing.
The cumulative gap of $360.8M between operating cash flow and net income suggests that the company's earnings quality is high, with cash flows consistently outpacing reported profits. This divergence may be attributed to significant depreciation and amortization, as well as stock-based compensation, which are non-cash expenses. However, the gap also reflects the volatility in net income, which included a large loss in Q2 2026, and investors should consider whether this trend will continue as the company faces margin headwinds.
Cash Flow Statement Obscures Costs
Stock-based compensation averaged $11.3M per quarter over the last ten quarters, as reported in the cash flow statement, which is added back to operating cash flow, potentially overstating cash generation relative to shareholder dilution.
While SBC is a non-cash expense, it represents a real cost to shareholders through dilution. The consistent SBC of around $11M per quarter suggests that a portion of operating cash flow is not truly available to shareholders, as it is offset by the issuance of new shares. Additionally, the cash flow statement does not fully capture the potential cash outflows from regulatory settlements or legal contingencies, which could be material given the company's history. Investors should adjust for these items when assessing the sustainability of free cash flow.